Advertisement
UK markets close in 2 hours 26 minutes

  • FTSE 100

    8,445.44
    +64.09 (+0.76%)
     

  • FTSE 250

    20,706.70
    +175.40 (+0.85%)
     

  • AIM

    790.76
    +7.06 (+0.90%)
     

  • GBP/EUR

    1.1626
    +0.0015 (+0.13%)
     

  • GBP/USD

    1.2522
    -0.0002 (-0.02%)
     

  • Bitcoin GBP

    50,252.22
    +1,180.23 (+2.41%)
     

  • CMC Crypto 200

    1,305.41
    -52.60 (-3.87%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • CRUDE OIL

    79.80
    +0.54 (+0.68%)
     

  • GOLD FUTURES

    2,372.20
    +31.90 (+1.36%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,788.92
    +102.32 (+0.55%)
     

  • CAC 40

    8,238.66
    +51.01 (+0.62%)
     
PROPERTY:

Homes with investment potential

These residential properties could bring in a good ROI

GSK's diabetes drug set for European approval

Reuters - UK Focus

LONDON, Jan 24 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan.

Albiglutide belongs to the same class of injectable GLP (SES: E1:MC0.SI - news) -1 drugs as Victoza, from Novo Nordisk (Other OTC: NONOF - news) , and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca (EUREX: AZNF.EX - news) .

A positive recommendation for a drug by the European Medicines Agency is generally followed by a marketing authorisation by the European Commission. GSK said a final decision was anticipated later this quarter.

Last year regulators in the United States pushed back an approval decision on the drug until April 15.